Sumitomo Pharma Co. Ltd. has patented aminomethylcyclohexane derivatives acting as muscarinic M4 receptor antagonists. As such, they are described as potentially useful for the treatment of neurodegenerative diseases, cerebrovascular disorders, brain injury, movement and psychiatric disorders.
Neurocrine Biosciences Inc. has described new muscarinic M4 receptor antagonists reported to be useful for the treatment of tremor, dystonia and parkinsonism.
Researchers from Cerevel Therapeutics LLC presented data from a study that aimed to evaluate preclinical antipsychotic properties of M4 agonism while minimizing off-target side effects using novel muscarinic acetylcholine M4 receptor full and partial agonists, CV-0000042 (CVL-042) and CV-0000071, respectively.
